close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Vertex Pharmaceuticals Incorporated

< Previous 1 2 3 4 5 Next >
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers CRSP VRTX
Vertex Appoints Nancy Thornberry to its Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers CRSP VRTX
Vertex Reports Third Quarter 2023 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Present at Upcoming Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Announce Third Quarter 2023 Financial Results on November 6
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Appoints Michel Lagarde to its Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Reports Second Quarter 2023 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Announce Second Quarter 2023 Financial Results on August 1
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers CRSP VRTX
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers CRSP VRTX
Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today